C&L: Forster wins tap to run Solace

Solace Pharmaceuticals has recruited Dr. Eliot Forster, most recently Pfizer's head of development for Europe and Asia, as its new CEO.

Bristol-Myers has removed "interim" from James Cornelius' title as CEO.

Anaptys Biosciences has named Tom Smart to the newly created position of chairman and CEO. Smart is the former chief business officer at XOMA Ltd.

Wyeth said CFO Kenneth Martin will leave the company at the end of June.

Compugen has appointed Ronit Lerner as CFO and Rachel Bart as general counsel.

Ligand Pharmaceuticals has named John P. Sharp vice president of finance and CFO. Sharp replaces Interim CFO Tod Mertes.

Gustav A. Christensen is joining Dyax as executive vice president and chief business officer.

Prime Therapeutics has promoted Kim Mageau to COO.

US Oncology announced that its COO, George Morgan, will retire effective June 30, 2007.

Lori A. Kunkel, M.D. has been hired as chief medical officer of Proteolix.

PTC Therapeutics has promoted Neil Almstead to senior vice president of chemistry and CMC, chemistry manufacturing and controls. 

Ilypsa has promoted Paul A. Stone to the position of senior vice president, general counsel and chief patent counsel. 

Viron Therapeutics has appointed Claude R. Benedict, M.D. as senior vice president, clinical development and regulatory affairs. 

David A. Saperstein, M.D. will be joining QLT as a consultant and interim chief medical officer and Paul L. Kaufman, M.D. was named head of the company's Ocular Scientific Advisory Board. 

Dermagenics U.S., Inc., a subsidiary of Greystone Pharmaceuticals, has named I. Kelman Cohen, M.D. chief medical director. 

Medicure has named Bonnie Zell as the company's senior advisor to commercial operations. 

Techne Corporation announced that Richard A. Krzyzek, Ph.D., has been appointed vice president of research for its biotechnology division, and that Dr. Monica Tsang, the company's vice president of research, has announced her intent to retire.

NicOx has recruited Sanjiv Sharma as vice president of commercial affairs.

Tengion announced that Dr. Sharon Presnell has joined the company as vice president for regenerative medicine and biology.

William Champion, M.S., has joined Critical Path Services as a senior research scientist at their analytical laboratory.

PrimeGen Biotech has named Dr. Rudolf Jaenisch, to its Scientific Advisory Board.

ImmuneRegen BioSciences has Frederick "Skip" M. Burkle, Jr. to its Bioterrorism/Pandemic Influenza Advisory Board. 

SinoBiomed announced that Dr. Dicken Shiu-Chung Ko, B.SC, M.D., F.R.C.S.C., F.A.C.S, has joined SinoBiomed's Advisory Board. 

Diffusion Pharmaceuticals has named the following to its new Scientific Advisory Board: John L. Gainer, Ph.D. (Chair); Stuart A. Grossman, M.D.; John A. Jane, M.D., Ph.D., FRCS; and David E. Longnecker, M.D., FRCA. 

The chairman of the board of directors of Epix Pharmaceuticals, Christopher F. O. Gabrieli, has decided to retire from the EPIX board.

INNOVIVE Pharmaceuticals has named Philip Frost, M.D., Ph.D., to the company's board of directors.

Oragenics announced that George Hawes is leaving his position as a member of the board.

Kyphon announced the appointment of D. Keith Grossman to its board of directors.

pSivida announced that Dr. Roger Aston, who joined the board as a non-executive director in December 2006, has resigned to focus on other activities including his role as the CEO of his new Australian based company, HalcyGen Pharmaceuticals Limited.

Adolor Corporation has elected Georges Gemayel, Ph.D. to its board of directors.

ImmunoGen has added Stephen C. McCluski to the company's board of directors.

Keryx Biopharmaceuticals has named Kevin J. Cameron to its board.

Allos Therapeutics has named Dr. Jeffrey R. Latts to its board.

Oculus Innovative Sciences has named Jay E. Birnbaum, Ph.D., to its board.

Bionovo has appointed Dr. Mimi Hancock to the company's board of directors.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.